138 related articles for article (PubMed ID: 10799817)
21. Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants.
Wei G; Jin L; Xu L; Liu Y; Lu W
Int J Pharm; 2010 Oct; 398(1-2):123-9. PubMed ID: 20674730
[TBL] [Abstract][Full Text] [Related]
22. Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone.
Stein S; Auel T; Kempin W; Bogdahn M; Weitschies W; Seidlitz A
Eur J Pharm Biopharm; 2018 Jun; 127():270-278. PubMed ID: 29490233
[TBL] [Abstract][Full Text] [Related]
23. Preparation of dexamethasone ophthalmic implants: a comparative study of in vitro release profiles.
Prata AI; Coimbra P; Pina ME
Pharm Dev Technol; 2018 Mar; 23(3):218-224. PubMed ID: 28300463
[TBL] [Abstract][Full Text] [Related]
24. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
25. From lactic acid to poly(lactic acid) (PLA): characterization and analysis of PLA and its precursors.
Inkinen S; Hakkarainen M; Albertsson AC; Södergård A
Biomacromolecules; 2011 Mar; 12(3):523-32. PubMed ID: 21332178
[TBL] [Abstract][Full Text] [Related]
26. PHEA-PLA biocompatible nanoparticles by technique of solvent evaporation from multiple emulsions.
Cavallaro G; Craparo EF; Sardo C; Lamberti G; Barba AA; Dalmoro A
Int J Pharm; 2015 Nov; 495(2):719-27. PubMed ID: 26410757
[TBL] [Abstract][Full Text] [Related]
27. Designing bioresorbable polyester matrices for controlled doxorubicin release in glioma therapy.
Kasperczyk J; Stoklosa K; Dobrzynski P; Stepien K; Kaczmarczyk B; Dzierzega-Lecznar A
Int J Pharm; 2009 Dec; 382(1-2):124-9. PubMed ID: 19715746
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants.
Ramchandani M; Robinson D
J Control Release; 1998 Jul; 54(2):167-75. PubMed ID: 9724903
[TBL] [Abstract][Full Text] [Related]
29. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.
Jain RA
Biomaterials; 2000 Dec; 21(23):2475-90. PubMed ID: 11055295
[TBL] [Abstract][Full Text] [Related]
30. Monitoring release of ketoprofen enantiomers from biodegradable poly(D,L-lactide-co-glycolide) injectable implants.
Wang SH; Liang ZH; Zeng S
Int J Pharm; 2007 Jun; 337(1-2):102-8. PubMed ID: 17296274
[TBL] [Abstract][Full Text] [Related]
31. Preparation and evaluation of biodegradable films containing the potent osteogenic compound BFB0261 for localized delivery.
Umeki N; Sato T; Harada M; Takeda J; Saito S; Iwao Y; Itai S
Int J Pharm; 2011 Feb; 404(1-2):10-8. PubMed ID: 21047548
[TBL] [Abstract][Full Text] [Related]
32. Preparation of Polymeric Prodrug Paclitaxel-Poly(lactic acid)-b-Polyisobutylene and Its Application in Coatings of a Drug Eluting Stent.
Ren K; Zhang M; He J; Wu Y; Ni P
ACS Appl Mater Interfaces; 2015 Jun; 7(21):11263-71. PubMed ID: 25955234
[TBL] [Abstract][Full Text] [Related]
33. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants.
Morita Y; Ohtori A; Kimura M; Tojo K
Biol Pharm Bull; 1998 Feb; 21(2):188-90. PubMed ID: 9514619
[TBL] [Abstract][Full Text] [Related]
34. Biodegradable poly (lactic acid) microspheres for drug delivery systems.
Hyon SH
Yonsei Med J; 2000 Dec; 41(6):720-34. PubMed ID: 11204823
[TBL] [Abstract][Full Text] [Related]
35. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization.
Camargo JA; Sapin A; Nouvel C; Daloz D; Leonard M; Bonneaux F; Six JL; Maincent P
Drug Dev Ind Pharm; 2013 Jan; 39(1):146-55. PubMed ID: 22397675
[TBL] [Abstract][Full Text] [Related]
36. Injectable microcapsules prepared with biodegradable poly(alpha-hydroxy) acids for prolonged release of drugs.
Ogawa Y
J Biomater Sci Polym Ed; 1997; 8(5):391-409. PubMed ID: 9105978
[TBL] [Abstract][Full Text] [Related]
37. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties.
Jalil R; Nixon JR
J Microencapsul; 1990; 7(3):297-325. PubMed ID: 2200861
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in the preparation progress of protein/peptide drug loaded PLA/PLGA microspheres.
Xu FH; Zhang Q
Yao Xue Xue Bao; 2007 Jan; 42(1):1-7. PubMed ID: 17520799
[TBL] [Abstract][Full Text] [Related]
39. Controlled DNA delivery systems.
Luo D; Woodrow-Mumford K; Belcheva N; Saltzman WM
Pharm Res; 1999 Aug; 16(8):1300-8. PubMed ID: 10468035
[TBL] [Abstract][Full Text] [Related]
40. Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing.
Witschi C; Doelker E
J Control Release; 1998 Feb; 51(2-3):327-41. PubMed ID: 9685930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
